A recent study reveals that individuals who come off new weight-loss injections like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who halt traditional lifestyle plans.
Findings released in a major medical journal shows that while obese individuals often shed substantial amounts of their total mass while using the jabs, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"People buying these drugs should be informed of the danger of fast rebound weight gain when the treatment concludes," stated expert Dr. Susan Jebb.
Such speed of regain suggests a return to original weight in about one and a half years.
Comparing Therapies
The analysis, which looked at dozens of studies involving over 9,000 of participants, compared the results of these new drugs with older methods.
Researchers emphasize that people who lose weight through lifestyle changes alone typically see a slower weight regain—perhaps 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Experts believe the mechanism of the drugs accounts for the amplified weight return.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal may cause the system to produce less of its own natural hormone, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' results in appetite is no longer kept in check, making excessive eating a significant risk."
A Chronic Issue?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts argue that, considering the significant potential of weight regain, the treatment is often life-long.
This opinion is reinforced by pharmaceutical companies, who note that the results "emphasize the chronic character of excess weight," akin to managing diseases like diabetes.
User Testimonies
Users who have discontinued the medication describe a intense resurgence of hunger.
"It was like something activating and I was suddenly ravenous," recalled one woman.
This difficulty is worsened if patients have not developed lasting lifestyle or habit changes during therapy.
Growing Adoption
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Use is greater among women compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, experts stress that while these medications are effective agents for weight loss, they are not a standalone solution and long-term success likely depends on combined lifestyle changes.
